Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Transplantation and Cellular Therapy|August 17, 2021
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic SyndromesBetül Oran, Kwang Woo Ahn, Caitrin Fretham, et al.
Transplantation and Cellular Therapy|August 24, 2021
Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in AdultsLeland Metheny, Natalie S Callander, Aric C Hall, et al.
JAMA Oncology|January 13, 2022
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated DonorsGuru Subramanian Guru Murthy, Soyoung Kim, Zhen-Huan Hu, et al.
Blood Advances|May 3, 2023
A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysisRoni Tamari, Donal P McLornan, Kwang Woo Ahn, et al.
Transplantation and Cellular Therapy|October 3, 2020
Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research StudyNelli Bejanyan, Meijie Zhang, Khalid Bo-Subait, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2020
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic SyndromesAziz Nazha, Zhen-Huan Hu, Tao Wang, et al.
Blood Advances|September 22, 2021
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AMLKamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin, et al.
Bone Marrow Transplantation|September 29, 2021
An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysisAntonio M Jimenez Jimenez, Marcos De Lima, Krishna V Komanduri, et al.
Transplantation and Cellular Therapy|January 26, 2022
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant ResearchHemant S Murthy, Kwang Woo Ahn, Noel Estrada-Merly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2019
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research ReportHaesook T Kim, Kwang Woo Ahn, Zhen-Huan Hu, et al.
Pageof 9